Literature DB >> 10902629

Oral contraceptives and fatal pulmonary embolism.

L Parkin, D C Skegg, M Wilson, G P Herbison, C Paul.   

Abstract

In a national case-control study of fatal pulmonary embolism in New Zealand women of childbearing age, we estimated that current users of combined oral contraceptives had a relative risk of 9.6 (95% CI 3.1-29.1). From national distribution data, the absolute risk of death from pulmonary embolism in current users was estimated to be 10.5 per million woman-years.

Entities:  

Keywords:  Biology; Case Control Studies; Contraception; Contraceptive Methods; Death Rate--women; Demographic Factors; Developed Countries; Diseases; Embolism; Family Planning; Mortality; New Zealand; Oceania; Oral Contraceptives; Oral Contraceptives, Combined; Population; Population Dynamics; Pulmonary Embolism--women; Research Methodology; Research Report; Risk Factors; Studies; Vascular Diseases; Women

Mesh:

Substances:

Year:  2000        PMID: 10902629     DOI: 10.1016/S0140-6736(00)02382-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Third generation oral contraceptives.

Authors:  D C Skegg
Journal:  BMJ       Date:  2000-07-22

2.  The third generation pill controversy ("continued").

Authors:  J O Drife
Journal:  BMJ       Date:  2001-07-21

3.  Diane-35 (cyproterone acetate): safety concerns.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-02-18       Impact factor: 8.262

Review 4.  Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

Authors:  Lamberto Manzoli; Corrado De Vito; Carolina Marzuillo; Antonio Boccia; Paolo Villari
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

5.  Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting.

Authors:  Karin Hedenmalm; Eva Samuelsson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?

Authors:  James Drife
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Authors:  Ida Martinelli; Anthonie W A Lensing; Saskia Middeldorp; Marcel Levi; Jan Beyer-Westendorf; Bonno van Bellen; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Mila Trajanovic; Martin Gebel; Phuong Lam; Philip S Wells; Martin H Prins
Journal:  Blood       Date:  2015-12-22       Impact factor: 22.113

Review 8.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

9.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

Authors:  A van Hylckama Vlieg; F M Helmerhorst; J P Vandenbroucke; C J M Doggen; F R Rosendaal
Journal:  BMJ       Date:  2009-08-13

10.  Hormonal contraception and risk of venous thromboembolism: national follow-up study.

Authors:  Øjvind Lidegaard; Ellen Løkkegaard; Anne Louise Svendsen; Carsten Agger
Journal:  BMJ       Date:  2009-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.